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Phantom Limb Pain is perceived pain in a region of the body that has been 
removed through amputation. It is a devastating syndrome affecting up to 80% of all 
post-amputation patients, however, no reliable treatment option currently exists. 
Pregabalin is proven to be effective in the treatment of similar symptoms of a diabetic 
neuropathic origin. We propose a double-blinded, randomized controlled trial to evaluate 
the effect of pregabalin in patients who experience Phantom Limb Pain. We expect the 
pregabalin treatment to produce a statistically significant change in mean pain from 
baseline as well as an improvement in quality of life factors in individuals suffering from 
Phantom Limb Pain. If proven effective, pregabalin will provide a crucial treatment 
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Chapter One: Introduction 
1.1    Background  
 The term Phantom Limb Pain (PLP) is defined as pain perceived in a region of the 
body that is no longer present due to amputation.1 It is a devastating syndrome marked by 
persistent pain within an amputated limb affecting 80% of all post-amputation patients 
regardless of whether the amputation has occurred in an upper or lower limb.1-5 
Symptoms generally include: burning, throbbing, aching, cramping or stabbing pain with 
sharp and stabbing pain noted as the most common forms of presentation.1-3,6 PLP can be 
debilitating for the patients experiencing this unique type of pain due to immense 
suffering and significant decrease in quality of life.7  
PLP was first described in the 16th century by the French military surgeon 
Ambrose Pare with the actual term Phantom Limb Pain coined in the 19th century by 
Silas Weir Mitchell, a famous Civil War surgeon.2,5,8 Once thought to be psychiatric in 
origin, the accumulation of recent research findings has shown the cause of PLP to be 
related to peripheral and central neural mechanisms, while psychological factors seem to 
influence the overall course and severity of the pain.2,5 As is the case with most 
neuropathic pain syndromes, diagnosis relies almost entirely on the history and physical 
examination.9 
A recent study estimated there were roughly 1.6 million people with limb loss in 
the United States in 2005; this number is expected to increase to 3.6 million people by the 
year 2050.2 Furthermore, the number of traumatic amputations as a result of military 
conflict in Iraq and Afghanistan has contributed significantly to the increasing rise of 
amputees within the veteran population.2 Since the start of the conflicts in Iraq and 
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Afghanistan, over 900 amputees have been treated at Walter Reed Army Medical Center 
in Washington, D.C.9 While PLP has increased due to amputations related to military 
conflict, PLP is not limited to just these cases. Diabetic patients who experience PLP 
after a surgical amputation appear to have a similar incidence, prevalence, and level of 
pain as compared to those individuals who have undergone a traumatic amputation.8 The 
most commonly reported reasons for limb loss include vascular problems, trauma, cancer 
and congenital limb defects.9 
 The complex etiology of PLP and overwhelming nature of the symptoms can 
make the management of PLP patients very frustrating for clinicians. A variety of 
treatments have been proposed, however, evidence-based guidelines for treatment are 
lacking, due in large part to the absence of properly controlled clinical trials.3,10 
Treatment modalities currently utilized by clinicians include pharmacologic and non-
pharmacologic approaches, though often with poor results.5 Pharmacotherapy modalities 
include opioids, tricyclic antidepressants such as Amitriptyline and N-methyl-D-aspartate 
(NMDA) receptor antagonists such as Memantine as well as nonsteroidal anti-
inflammatory drugs (NSAIDs).2,5 A cross sectional study found acetaminophen and 
NSAIDs to be the most common medications used in the treatment of PLP however trial 
results have been poor, especially in individuals who describe their pain to be moderate 
to severe.2 Non-pharmacologic modalities include noninvasive therapy such as mirror 
therapy and biofeedback, as well as invasive surgical procedures which include stump 
revision and rhizotomies.2,5 Controlled studies investigating treatments for PLP are 
generally lacking, but a limited number of clinical trials have shown a maximum benefit 
of about 30% from these treatment modalities, a proportion which does not exceed the 
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placebo effect.5,6,11 A summary of currently proposed treatments for PLP is found in 
Table 2.1.  
Nociceptive pain usually responds well to traditional analgesics while neuropathic 
pain is much less responsive to most medications, making the treatment of PLP much 
more difficult to manage.6 Specific mechanism-based treatments are still evolving as 
most treatments for PLP are based on neuropathic pain trials.2 Previous studies 
researching the use of anticonvulsants, such as pregabalin and gabapentin, have been 
shown to be effective in the treatment of similar painful neuropathic syndromes such as 
painful diabetic peripheral neuropathy and post-herpetic neuralgia. No studies have been 
performed to date, however, investigating the effect of these medications in the treatment 
of painful symptoms related to PLP.12-14 
 
1.2    Statement of the Problem 
 No reliable treatment option currently exists for the treatment of symptoms 
related to PLP.9 Current treatment options are left to clinician discretion and no 
standardized guidelines exist. This is likely due to the lack of evidence-based medicine 
with these treatment options having little to no effect on painful symptoms or overall 
quality of life.6 Previous studies have exhaustively researched the use of anticonvulsants, 
such as pregabalin and gabapentin, for the treatment of painful neuropathic syndromes 
like diabetic peripheral neuropathy and post-herpetic neuralgia and these medications 
appear promising for the treatment of PLP.12-14 
When taking into account that 80% of all individuals with an amputation will 
experience PLP at some point in their lives, it is clear to see the tremendous impact this 
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syndrome has on an increasingly larger percentage of the general population.1,2,5 The 
literature contains a few scattered case reports, case series and letters to the editors with 
extremely underpowered studies attempting to investigate treatment modalities for PLP 
yet few high-quality randomized controlled trials exist to-date.8 PLP remains a somewhat 
poorly understood and difficult to treat medical condition with a wide variety of different 
treatment regimens employed but mechanism-based treatment guidelines have yet to 
evolve.2 Given the incredibly high prevalence, age of onset and decreased quality of life 
due to limited effective treatment options for PLP, further studies are clearly needed. 
 
1.3    Goals and Objectives  
 This study aims to investigate the effects of pregabalin on symptoms related to 
PLP in amputee patients. The primary outcome of the study will be the mean decrease in 
pain from baseline after 15 weeks of pregabalin intervention versus placebo. The primary 
outcome will be measured via the Numeric Rating Scale (NRS) Tool for Self-Reporting 
of Pain where 0 is no pain and 10 is the worst possible pain. Secondary outcomes of the 
study will be the mean increase in quality of life measurements from baseline after 15 
weeks of pregabalin intervention versus placebo. The secondary outcomes, which will 
include physical functioning, social functioning, role limitations attributable to physical 
problems and general mental health, will be measured via the SF-36 (Short Form) Health 
Survey. If proven effective, pregabalin could provide a crucial treatment option for 




1.4    Hypothesis 
Primary Hypothesis 
 Among patients experiencing symptoms related to PLP, a mean decrease in pain 
from baseline to 15 weeks will be noted in participants who receive pregabalin treatment 
as compared to a placebo control group. Pain symptoms will be assessed at baseline as 
well as weekly for 15 weeks via an Interactive Voice-Response (IVR) System using the 
NRS Tool For Self-Reporting of Pain and a daily pain diary. Medication compliance will 
be monitored using Radiofrequency Identification (RDIF) technology. 
 
Secondary Hypothesis 
 Among patients experiencing symptoms related to PLP, there will be a mean 
increase from baseline in quality of life measures to include:   
a) Physical functioning, assessed by the SF-36 Health Survey, as compared to 
the placebo control group after 15 weeks of intervention. 
b) Social functioning, assessed by the SF-36 Health Survey, as compared to the 
placebo control group after 15 weeks of intervention. 
c) Role limitations attributable to physical problems, assessed by the SF-36 
Health Survey, as compared to the placebo control group after 15 weeks of 
intervention. 
d) General mental health, assessed by the SF-36 Health Survey, as compared to 




1.5    Definitions 
• IVR (Interactive Voice-Response) System: Automated voice response system 
where study participants record daily pain scale and sleep diary results as well 
as report the total number of medication doses taken throughout the day.15  
• NRS (Numeric Rating Scale) Tool For Self-Reporting of Pain: One of the 
most common measures of pain intensity used by clinicians and researchers 
alike.16  
• RFID (Radiofrequency Identification) Technology: Novel compliance 
monitoring system that embeds RFID tags into prescription blister packaging 
to allow for direct electronic monitoring of the date and time a patient or 
research participant opens a medication package.17 
• SF-36 (Short Form Health Survey): Quality of life instrument for measuring 
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Chapter Two: Literature Review 
2.1    Introduction 
 An extensive review of the medical literature was performed using Ovid 
MEDLINE and PubMed to review high quality peer-reviewed articles from 1946 through 
June 2015. Search results were limited to reviews and randomized controlled trials and 
then further narrowed down to include only articles written in English. Furthermore, 
articles were only included in the final literature review if they were peer-reviewed 
articles involving the use of adult human subjects. A final search of the literature was 
completed on June 22, 2015.  
Keywords used to complete the literature review included Phantom Limb Pain, 
pregabalin or Lyrica, acetaminophen, Diabetic Neuropathies, pain measurement and 
pain instrument. The aforementioned keywords were then combined in a number of ways 
using the search features found in PubMed. While a majority of the articles were from 
United States publications, a very small number of international articles were included in 
the literature review. Initially, articles were examined based on the title and abstract to 
ascertain their relevancy to the proposed study. Once articles were screened using these 
parameters, full text versions of the articles were obtained and thoroughly examined for 
relevancy and applicability. 
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2.2    Review of the Relevant Literature  
Phantom Limb Pain  
 High quality randomized controlled trials investigating the treatment of 
PLP are severely lacking in the literature.1 In 2002, Bone et al. attempted to examine the 
effectiveness of gabapentin in the treatment of PLP in a placebo-controlled cross-over 
trial with a one-week wash-out period. Randomization was achieved via computer-
generated randomization. Participants consisted of patients with PLP for greater than 6 
months with an average pain intensity greater than 40/100 on the VAS (Visual Analog 
Scale). A total of 19 subjects (15 males versus 4 females) participated with a mean age of 
56.25 years and a baseline mean pain intensity of 6.1/10. Interventions included 
gabapentin titrated in increments of 300 mg up to a maximum dose of 2,400 mg/day for 6 
weeks compared to a placebo arm to analyze an outcome of a decrease in pain intensity, 
as well as changes in mood and depression in the treatment arm versus the placebo arm. 
Results showed a statistically significant difference in patient reported pain in the 
gabapentin arm (p = 0.03, CI = 95%) when compared to the placebo arm, while no 
changes were noted in mood or depression in the gabapentin arm when compared to the 
placebo arm. No adverse events were noted throughout the duration of the study. 
Strengths of the study lie in the design, as the randomization and blinding techniques 
limited the possibility of bias. Limitations of the study come in the form of a very small 
effect size limiting the generalizability and validity of the data. Researchers noted larger 
scale studies are warranted in order to better investigate the effects of gabapentin on 
mood, sleep interference and activities of daily living.2  
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In 2001, Huse et al. investigated the effect of morphine in the treatment of PLP in 
a randomized crossover study lasting four weeks with a one to two week washout period. 
Pain was measured on a 0-100 VAS comparing the morphine arm of the study to the 
placebo arm. A total of 12 subjects (10 males versus 2 females) participated in the study 
with a mean age of 50.58 years and a baseline pain intensity of 4.6/10 using the VAS. 
The interventions were oral morphine sulfate titrated from 70 mg/day up to 300 mg/day 
to a maximum tolerable dose for four weeks. Primary outcome was a change in pain 
intensity as compared to baseline using the VAS. Secondary outcomes included a change 
in mood and depression as well as quality of life measures via the West Haven Yale 
Multidimensional Pain Inventory. Results showed a statistically significant decrease in 
pain in the morphine arm versus the placebo arm (p = 0.036, CI = 95%) with about 42% 
of participants experiencing greater than 50% pain relief. Secondary outcomes failed to 
show a statistically significant difference in the morphine arm compared to the placebo 
arm. Reported adverse effects in the morphine arm included tiredness, dizziness, 
sweating, constipation, vertigo, itching and shortness of breath. This study had significant 
limitations in terms of design. The sample size was far too small to appropriately 
interpret the results of this study. More importantly, bias was almost certainly introduced 
as blinding was not maintained throughout the course of the study. Participants and 
physicians alike were able to identify the morphine treatment participants due to the 
observable nature of morphine side effects. Furthermore, the study lasted only four weeks 
in duration.3 
In 2005, Smith et al. investigated the effect of gabapentin in the treatment of PLP 
in a randomized, double-blinded crossover study lasting six weeks with a five-week 
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washout period. Randomization was achieved via computer generated randomization 
techniques. Participants comprised patients with an upper or lower extremity amputation 
currently experiencing PLP with a minimum of six months status post amputation and an 
average pain scale of 3/10 using the Numeric Rating Scale (NRS). A total of 24 
participants (18 males versus 6 females) were included in the study with a mean age of 
52.1 years and a baseline mean pain intensity of 4.3/10. Interventions included 
gabapentin titrated from 300-3600 mg per day for six weeks. The primary outcome was a 
mean change in pain intensity in the gabapentin arm when compared to the placebo arm. 
Secondary outcomes were a mean change in mood and depression as well as changes in 
quality of life. Results failed to reach statistically significant levels for either the primary 
or secondary outcome. The study was limited by the significantly underpowered effect 
size. Strengths of the study stem from the randomization technique as well as the similar 
baseline characteristics of the participants in terms of pain and location of amputation.4 
 
Current Treatment Options For Phantom Limb Pain  
 Multiple studies demonstrate current treatments for PLP to be practically 
ineffective.5 The treatment of PLP is complicated by the complex origin of patient pain, 
which is estimated to involve both a nociceptive as well as neuropathic component, 
where neuropathic pain is described as pain in the absence of an external painful 
(nociceptive) stimulus.6,7 Most researchers consider PLP to be mostly of a neuropathic 
origin, with treatment recommendations based on known treatments of neuropathic pain 
syndromes.8 Patients with neuropathic pain are very challenging to manage due to a lack 
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of evidence-based clinical guidelines alongside the need for individualized therapies.9 A 
summary of currently proposed treatments for PLP is found in Table 2.1. 




Opioids Stump revision Transcutaneous Nerve Stimulation 
Tramadol Nerve block Mirror Therapy 
Tricyclic Antidepressants Neurectomy Biofeedback 
     Amitriptyline Rhizotomy Massage 
     Nortriptyline Cordotomy Ultrasound 
Anticonvulsant Lobectomy Physiotherapy 
     Carbamazepine Sympathectomy Sensory Discrimination Training 
     Oxcarbazepine CNS Stimulation Prosthesis Training 
     Gabapentin  Electroconvulsive Therapy 




     Memantine   
 
Pharmacologic Treatments  
Anticonvulsants 
Gabapentin has shown mixed results with a few randomized controlled trials, 
some of which demonstrate encouraging results and others failing to show efficacy. 
These trial sample sizes, however, have been too small to draw appropriate conclusions 
from.8,10 Pregabalin has been shown to be very safe with the most frequent adverse events 
noted to be dizziness, somnolence, peripheral edema, headache and dry mouth.9,11,12 To 
date, there have been no studies investigating the effectiveness of pregabalin as a 




Antidepressants   
With their analgesic action attributed to serotonin-norepinephrine blockade 
combined with sodium channel blockade, tricyclic antidepressants are some of the most 
commonly prescribed medications for neuropathic pain, including PLP, although study 
results have been very mixed in terms of their role in PLP treatments.13 Not only have the 
study results not demonstrated significant findings, but tricyclic antidepressants have a 
number of known adverse reactions which include sedation, orthostatic hypotension, 
aggravation of pre-existing cardiac rhythm disorders, as well as anticholinergic effects 
such as dryness of the mouth, constipation and urine retention.6  
 
Calcitonin 
The mechanism of action of calcitonin remains unclear in the treatment of PLP 
with study results yielding mixed results.8 Clarke et al. has demonstrated a potential 
benefit of calcitonin treatment if used at the early onset of PLP, but studies conducted 
outside of the acute onset of PLP symptoms have not demonstrated any benefit from use.1 
 
NMDA Receptor Antagonists 
The mechanism of action of NMDA receptor antagonists in the treatment of PLP 
is unclear. The use of Memantine has shown some potential benefits in case studies, 





  Opioids  
Opioids have demonstrated some effectiveness in the treatment of neuropathic 
pain including PLP.9 Comparative trials investigating the benefit of opioids compared to 
tricyclic antidepressants have shown that while more side effects were noted with opioid 
treatments, they appear to be just as effective. These studies, however, have not been 
properly powered.3,8. Concern for potential addiction and prescription abuse makes many 
clinicians reluctant to treat PLP with opioids.6 
 
Non-Pharmacologic Treatments 
Biofeedback & Complimentary Medicine 
Earlier reports suggest temperature biofeedback may be helpful for the treatment 
of the burning sensation associated with PLP, but no specific evidence has been 
demonstrated in clinical trials.8 While complementary medicine and biofeedback 
continues to be widely used in some countries, herbal medicine, acupuncture, muscle 
relaxation and biofeedback have not been formally assessed in a controlled setting.6  
 
Electroconvulsive Therapy (ECT) 
A case report describing a positive outcome of ECT for the treatment of PLP has 
been published however the mechanism and role of ECT is not well understood and no 






 Ramachandran and Rogers described mirror therapy in 1996 as a potential novel 
treatment for symptoms related to PLP. Through this therapy, patients insert their intact 
limb into a box containing a mirror creating the illusion that both limbs are present. 
Patients are then instructed to move their hands or feet in order to mimic real movement 
in their missing limb and potentially reproduce cognitive awareness of the missing limb.5 
While certainly an interesting and cost-effective approach to the treatment of PLP, 
randomized controlled trials have yielded mixed results.8 
 
Surgical Intervention 
 Surgical intervention is traditionally utilized when pharmacologic and non-
pharmacologic modalities have failed.5 Studies resulting in good data investigating the 
effect of surgical treatment are lacking. Techniques utilized in the past include rhizotomy, 
cordotomy, thalmotomy and cortical resections.6 Although there certainly may be a role 
for surgical intervention in the treatment of intractable PLP, additional studies are 
required before a conclusion may be reached.8 
 
Diabetic Peripheral Neuropathy 
Diabetic Peripheral Neuropathy (DPN) is a debilitating and distressing 
complication of diabetes mellitus that develops in up to 30-50% of diabetic patients.14 
DPN is defined as the presence of symptoms of peripheral nerve dysfunction with 
symptoms described as burning, electric, sharp, achy and stabbing.15 In addition to the 
physical symptoms, neuropathic pain can lead to a negative impact on the quality of life 
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of an individual and can have devastating effects on their daily living, mood and 
sleep.14,15 Neuropathic pain can be difficult to treat and can be taxing on both the 
clinician and the patient as patients rarely experience complete relief of their painful 
symptoms.14,16 Of the many treatment options for DPN, Pregabalin has some of the 
strongest evidence-based support demonstrating its effectiveness in the treatment of 
painful symptoms in patients with DPN.14,17 
In a 2008 meta-analysis, Hurley et al. examined the effects of pregabalin on 
painful DPN as it relates to pain control, sleep disturbances and the Patient Global 
Impression of Change (PGIC) by analyzing data from three different randomized 
controlled trials with a total of 728 subjects from five different centers. Primary outcome 
was a change in pain intensity at the conclusion of the study when compared to baseline 
pain values. Secondary outcomes included the number of patients with greater than a 
50% reduction in mean pain as compared to baseline score as well as PGIC ratings at 
endpoint as compared to baseline. Results of the meta-analysis showed a significant 
decrease in pain in the pregabalin arms when compared to the placebo arm (weighted 
mean difference of 1.15, CI: 95%). Secondary outcomes also demonstrated favorable 
results in the pregabalin arm versus the placebo arm. The conclusion of the meta-analysis 
demonstrated pregabalin to have significant effects on the pain associated with DPN as 
well as impacting overall quality of life. Strengths of the study lie in the power of the 
meta-analysis given the large subject size of 728 total subjects. Limitations stem from the 
overall design of a meta-analysis given the strength of a meta-analysis lies solely on the 
articles being evaluated. Additionally, pregabalin dosages in each of three randomized 
controlled trials were not uniform which may have had an effect on the data analysis.18 
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A 2008 study conducted by Arezzo et al. investigated the efficacy and safety of 
pregabalin 600 mg/day in the treatment of painful DPN via a double-blind placebo-
controlled trial lasting 12 weeks with a week-long dosage escalation period. Pain was 
measured using the NRS pain scale. A total of 167 subjects participated in the study with 
82 in the pregabalin arm and 85 in the placebo arm. In the placebo arm of the study, 45% 
were male versus 58% in the pregabalin arm and the mean age was 58.2 years with a 
mean baseline pain intensity of 6.5/10. Primary outcome was a change in pain intensity as 
compared to baseline using the NRS pain scale. Secondary outcomes included sleep 
interference and quality of life measurements via the Short-Form McGill Pain 
Questionnaire (SF-MPQ). Randomization was achieved using a computer-generated 
random code. Statistical analysis of both the primary and secondary endpoints was 
achieved using Analysis of covariance (ANCOVA). Results showed a statistically 
significant decrease in pain in the pregabalin arm versus the placebo arm (p=0.0003, CI: 
95%) with 49% of responders experiencing greater than 50% pain relief. Secondary 
outcomes of a change in sleep interference as well as improvement in quality of life 
measurements also showed a statistically significant difference in the pregabalin arm 
compared to the placebo arm (p=0.0019, CI: 95%). Reported adverse effects included 
peripheral edema and dizziness with peripheral edema being the most common side 
effect. This was a very well designed study with no apparent limitations. Overall 
strengths of the study stem from the appropriate effect size as well as strict inclusion and 
exclusion criteria to attempt to minimize potential confounders.19   
 A groundbreaking 2004 study conducted by Lesser et al. demonstrated the 
efficacy of pregabalin in the treatment of painful symptoms related to DPN via a double-
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blind placebo-controlled trial lasting five weeks including an initial weeklong titration 
phase. Subjects were randomized into one of three different dosage arms (75mg/day, 300 
mg/day or 600 mg/day) or into the placebo arm. Pain was measured using the NRS pain 
scale. A total of 338 subjects participated in the study with 77 in the 75mg/day arm, 81 in 
the 300 mg/day arm, 82 in the 600 mg/day arm and 97 in the placebo arm. Of the 338 
subjects, 60% of the participants were male with 95% identifying themselves as 
Caucasian. The mean age was 60 years of age with a mean baseline pain intensity of 
6.4/10. The primary outcome was a change in pain intensity as compared to baseline 
using the NRS pain scale. Secondary outcomes were daily sleep interference and quality 
of life assessments utilizing the SF-MPQ and the SF-36 Health Survey. Randomization 
was achieved via a randomized computer generated code with a block size of eight. 
Statistical analysis of both the primary and secondary endpoints was achieved using 
ANCOVA.  
Result of the study showed a statistically significant decrease in pain in the 300 
mg/day (p=0.0001, CI: 95%) and 600 mg/day (p=0.0001, CI: 95%) pregabalin arms of 
the study respectively with the 75mg/day arm failing to show a statistically significant 
difference. Data showed that 46% of the 300mg/day arm and 48% of the 600 mg/day arm 
achieved a greater than 50% reduction in mean pain scores when compared to baseline. 
Secondary outcomes analyzing sleep interference and overall quality of life 
measurements also demonstrated a statistically significant difference in the 300mg/day 
(p=0.0001, CI: 95%) and 600 mg/day (p=0.0001, CI: 95%). Results of this study 
demonstrated a dose-response relationship for pregabalin with the 300 mg/day and 600 
mg/day arm showing drastic differences in overall pain and quality of life measurements 
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when compared to the 75mg/day arm. Reported adverse effects included dizziness and 
somnolence and peripheral edema with dizziness being the most common side effect. Of 
interest, side effects were noted much more in the 600 mg/day arm than in the 300 
mg/day and 75 mg/day arm. The sample size of the study was a major strength with the 
Lesser study being the largest DPN double-blind, placebo-controlled trial ever conducted. 
Additionally, comparing different strengths of pregabalin in a head to head trial made for 
a very well organized study overall. This study was not without limitations, however. The 
study duration was only scheduled for five weeks. Ideally, chronic pain studies should be 
investigated for longer treatment periods with the optimal length being greater than 12 
weeks in order to demonstrate durability of the treatment response.20 Furthermore, 




Post-herpetic neuralgia (PHN) is defined as pain following an acute attack of 
herpes zoster with similar symptoms as PLP which include burning, lancinating or 
stabbing pain.11 Incidence for the development of PHN following an acute attack of 
herpes zoster ranges from 10-15%.9 Additionally, more than half of all patients with PHN 
will experience some form of sleep disturbance along with decreased daily activities as 
also noted in PLP.11 Tricyclic anti-depressants and opioid analgesics have been shown to 
be effective in the management of PHN pain, however, prevalence of side effects and 
medication addiction is a pressing concern.22 Pregabalin has been shown to be effective 
for the management of pain related to PHN in multiple studies.9,11  
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In a 2003 study, Dworkin et al. looked at the use of pregabalin for the treatment of 
PHN via a randomized controlled trial. In this study, 173 participants were randomized to 
either the pregabalin treatment arm (n=89) or the placebo arm (n=84) with the treatment 
arm receiving 600 mg/day (200 mg every 8 hours) of pregabalin. The primary endpoint 
was a mean reduction in pain in the pregabalin arm as compared to the placebo arm of the 
study via the NRS Pain Scale. Secondary endpoints included measurements of sleep 
interference, quality of life and mood via the SF-36 Health Survey as well as the Profile 
of Mood States. Study participants were defined as men and women who were at least 18 
years of age and had PHN, defined as pain present for three or more months after the 
healing of a herpes zoster rash. All analysis was performed using the Intent-to-Treat 
population defined as any patient who received at least one dose of study medication. 
Primary and secondary analysis was performed via ANCOVA. Results of the study 
showed 63% of the pregabalin arm versus 25% of the placebo arm reporting reductions in 
their pain of 30% or more (p=0.001, CI = 95%), which demonstrated a clinically 
important degree of pain relief. Additionally, 50% of the pregabalin arm versus 20% of 
the placebo arm reported a 50% decrease in their pain (p<0.005, CI = 95%), which 
demonstrated a statistically significant difference. Sleep interference scores were also 
statistically significant in the treatment arm (p=0.0001, CI = 95%) but while the quality 
of life measurements as assessed by the SF-36 Health Survey did show favorable results 
in the treatment arm, these results failed to reach significant levels (p=0.051, CI = 95%). 
The results of this study show pregabalin to be effective in relieving painful symptoms 
related to PHN and may indicate pregabalin as a treatment option for similar neuropathic 
pain syndromes.9  
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 While these results are very promising in terms of the use of pregabalin to treat 
symptoms related to PHN, the study may have introduced potential confounders in that 
the participants of the study were noted to be 95% Caucasian and were permitted to take 
opioid and non-opioid analgesics throughout the duration of the study, with as many as 
68% of the control arm using some form of these medications at some point during the 
trial. Additionally, the researchers decided on a pregabalin dose of 600 mg/day (200 mg 
every 8 hours) although it has previously been shown that while there may be an 
increased benefit of giving pregabalin at 600mg/day as compared to 300 mg/day for the 
relief of pain symptoms, adverse effects are dose dependent and noted more frequently in 
the 600 mg/day cohort.21 Strengths of the study lies in the study design as well as the 
nearly equal distribution of men versus women. 
In a 2004 study, Sabatowski et al. set out to investigate the efficacy and safety of 
pregabalin, and what effect pregabalin had on the reduction of pain, sleep and mood 
disturbances in patients with post-herpetic neuralgia via a randomized, placebo-controlled 
clinical trial. In this study, 238 participants were randomized into 3 arms: a pregabalin 
150 mg every eight hours arm (n=81), a 300 mg every eight hours arm (n=76) or a 
placebo arm (n=81) for a total of 8 weeks. The primary endpoint was a mean reduction in 
pain scores in those receiving 150mg or 300 mg pregabalin when compared to placebo. 
The secondary endpoints included mean sleep interference scores, quality of life 
measurements via the Short Form-36 (SF-36) Health Survey Form and depression scores 
via the Zung Self-Rating Depression Scale. 
 Efficacy analysis as well as safety analysis was based on the Intent-to-Treat 
population (ITT population) which was defined as all randomized patients who received 
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at least one dose of study medication. Primary and secondary analysis was performed via 
ANCOVA with treatment and clusters, or group of centers, as the fixed effects and the 
baseline scores as the covariate. Results of the study showed a significantly lower mean 
pain score for both the pregabalin 150 mg arm (p=0.006, CI = 95%) as well as the 
pregabalin 300 mg arm (p=0.003, CI = 95%) of the study when compared to placebo. 
Additionally, subjects in both the 150 mg and 300 mg pregabalin arms of the studies 
demonstrated significantly reduced weekly mean sleep interference scores as well as 
improvements in quality of life measurements (p=0.043, CI = 95%) when compared to 
placebo with efficacy observed as early as week 1 and maintained throughout the course 
of the study. This confirmed the findings of Dworkin et al. where pregabalin showed a 
significant decrease in the painful symptoms of PHN (p=0.0001, CI = 95%)as compared 
to placebo.9 Based on the results of this study, pregabalin shows promise as a therapy for 
PHN and may possibly be effective for the treatment of other various neuropathic pain 
syndromes as well.  
 While the results of this study were certainly very promising, the design was not 
without limitations. Sponsors of the study helped with the development and approval 
processes of the study as well as assisted with the management, biostatistical analysis and 
provided editorial assistance for the publication. Furthermore, 15 of the 307 subjects 
screened for inclusion in the study were excluded for “administrative or other reasons”. 
The sponsor’s participation in various aspects of the study alongside the exclusion of the 
15 mentioned subjects without definitive reasoning may all be sources of bias. 
Additionally, potential confounders can be seen in researcher’s allowance of participants 
continued use of medications throughout the duration of the study, including opioid and 
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non-opioid analgesics and antidepressants as well as each of the participants being 
identified as Caucasian. Strengths of the study lie in the study design itself with a very 
rigorous definition of what constituted a response, defined as a decrease in mean pain 
score of at least 50% from baseline to endpoint.11 
 
2.3    Review of the Relevant Methodology 
The purpose of this section is to review the methodologies and study designs of 
previous relevant studies in order to justify the proposed methodology and study design.  
Study Design 
 The proposed study will be a randomized controlled trial investigating the effect 
of pregabalin on the treatment of symptoms related to PLP. The randomized controlled 
trial study design is a proven hallmark for demonstrating the effectiveness of 
medications. The intervention will be pregabalin 300 mg/day compared to a placebo arm. 
Similar to the Sabatowski et al. study, both arms of the study will be permitted to use 
acetaminophen or ibuprofen for breakthrough pain management as it is unnecessary and 
perhaps unethical to withhold all forms of analgesic from the placebo arm.11,23 The 
biggest limitation of the Lesser trial is that it was shorter in duration than would normally 
be ideal for chronic pain studies.20,21 The proposed study will be similar to the Arezzo et 




Poor adherence to medication compliance has been a consistent barrier to 
clinicians achieving better clinical outcomes for their patients.24 This same barrier holds 
true for clinical researchers relying on study participants to take their medications as 
directed. Studies have demonstrated that as many as 50% of all patients do not adhere to 
their prescription medication regimen.24 One novel approach that may solve this 
compliance dilemma is through the use of RFID technology.25 Mediary Corporation, 
located in Ontario, Canada, has invented a RFID compliance monitoring system that 
embeds RFID tags into the prescription blister packaging to allow for direct electronic 
monitoring of the date and time a patient or research participant opens a medication 
package.25,26 This technology allows the investigation team to scan the used packaging 
where a subsequent usage pattern can then be plotted and analyzed for compliance.25 The 
plotted data would not only aid the research team in verifying compliance, but also would 
be beneficial for validating side effect complaints by analyzing the time dosages were 
taken and comparing this to self-reported adverse effects. Furthermore, the RFID 
technology also has the capability to alert a patient or research participant to take their 




 Similar to the study by Jensen et al., participants from this study will be recruited 
from various Department of Veteran Affairs (VA) Hospitals.27 The VA hospital system is 
not only home to one of the oldest electronic medical record (EMR) systems in the 
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country, but through a joint effort between the Department of Defense and Department of 
Veteran Affairs, all Iraq and Afghanistan related traumatic amputations are closely 
tracked by Walter Reed Army Medical Center in Washington, D.C. allowing for a larger 
pool of potential study participants.10 Strict inclusion and exclusion criteria will be 
enforced in order to minimize confounders. Inclusion criteria will include: timeline of six 
months or greater since amputation from the start of the study4, confirmation of 
neuropathic pain via a score of 12 or greater on the Leeds Assessment of Neuropathic 
Symptoms and Signs (LANSS)15, average daily pain of 4/10 or greater11,19 and female 
subjects will be required to be non-pregnant and non-lactating9,11. Subjects presenting 
with any of other cause of painful neuropathy to include B12 deficiency, hypothyroidism, 
uremia or diabetic peripheral neuropathy14,17 and subjects whose Creatinine clearance 
rates are ≤ 60 mL/min using the Cockcroft-Gault equation will be excluded from the 
study19,21. 
 
LANSS Pain Scale 
 Interested participants will initially be screened to verify the source of pain as 
neuropathic in origin versus that of nociceptive or psychogenic via the LANSS pain 
scale. The LANSS pain scale is a screening tool designed to aid clinicians and 
researchers in distinguishing neuropathic pain from pain of a different origin.28,29. This 
tool consists of a total of 7 items: a 5-item questionnaire to determine pain symptoms as 
well as 2 items that involve a clinician administered test to evaluate for the presence of a 
decreased sensation to pin prick as well as allodynia, or a pain response from a stimulus 
which would normally not provoke a painful response.30 The binary responses of ‘yes’ or 
 26 
‘no’ are each weighted differently depending on the odds ratio of a positive response as 
predictive of pain as neuropathic in origin. The responses are then tallied with possible 
scores ranging from 0 to 24 with a score of 12 or more considered suggestive of pain as 
neuropathic in origin.15,30 Sensitivity for the LANSS Pain Scale ranges from 74-78% 
along with a specificity of 80%.28,30 The internal consistency and validity of the LANSS 
has been tested in a number of different settings and has been confirmed to be a valid and 
reliable instrument for distinguishing pain of neuropathic origin.28  
Intervention 
Pregabalin 
Pregabalin is an alpha2-delta ligand with analgesic, anxiolytic, and anticonvulsant 
properties.9,11,12 Potent binding at the alpha2-delta receptors reduces calcium influx at 
nerve terminals which in turn decreases the release of several neurotransmitters 
responsible for pain transmission like glutamate, noradrenaline and substance P with the 
analgesic effects being two to four times more potent than gabapentin in the treatment of 
neuropathic pain with remarkable safety and efficacy.12,31 Other known benefits of 
pregabalin include improvements in both sleep disturbances and anxiety, and a very mild 
side effect profile which includes dizziness, somnolence, headache, dry mouth, peripheral 
edema, weight gain and blurred vision.13 The only known contraindication to pregabalin 
is renal insufficiency.12 The dosage of pregabalin was adopted from the Dworkin et al. 
and Lesser et al. studies which both showed a dose of 300 mg/day with an appropriate 
titration to be an effective treatment option for DPN with little to no side effects noted.9,21 
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Primary Outcome Measures 
NRS Pain Scale 
 Pain intensity and severity are the single most frequently assessed variables in 
clinical research investigating pain treatment.27 The primary outcome of the proposed 
study will be a mean change from baseline in patient reported pain as measured via the 
NRS pain scale. This primary outcome was chosen based on a number of prior studies 
investigating potential treatments for symptoms related to the treatment of painful 
neuropathy.11,20-22,32-36 The NRS is a pain scale designed to measure pain intensity where 
0 = no pain and 10 = the worst possible pain imaginable and is widely used to assess 
pain.37,38 Pain scales such as the NRS have been deemed psychometrically sound and are 
easily interpreted by patients and clinicians alike. Additionally, the NRS is often 
considered a first-line pain severity scale when sensitive and responsive measures of pain 
intensity are required.39 For these reasons, the NRS has been widely used in the 
evaluation of pain severity in both clinical and research settings.40  
It is not only necessary to assess the level of pain experienced but to also stratify 
pain into “mild”, “moderate” and “severe” categories based on the impact pain has on 
quality of life.27,40 Through multiple post hoc analysis of placebo-controlled trials, cut 
points have been established as “mild” being 1-3, “moderate” being 4-6 and “severe” 
being 7-10 based on symptom similarities within the three groups with pain beginning to 
have a serious impact on functioning and quality of life when it reaches a level of 5 out of 
10.27,38,40 A reduction in pain of two points from baseline has been shown to be 
statistically significant.37 
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In a 2010 study, Hoffman et al. attempted to investigate how changes in pain 
severity levels corresponded to changes in health status and function in patients with 
painful diabetic peripheral neuropathy via a post hoc analysis of a 12-week, multi-
national, placebo-controlled trial of pregabalin for the treatment of diabetic peripheral 
neuropathy. In this study, 401 patients were analyzed in order to establish NRS cut-points 
as well as describe the relationship between changes in pain levels and what effect this 
change has in function and health status. Investigators in this study sought to establish the 
level of improvement in pain necessary to demonstrate a statistically significant 
difference as well as to establish what clinical meaningfulness could be extrapolated from 
this data. The results indicated the cut-points established by previous studies were 
consistent when compared to different health related measures. These findings served to 
provide evidence of convergent validity as well as to help confirm NRS pain scales as a 
well-validated tool for establishing pain severity. When changes in pain levels were 
compared to changes in quality of life metrics, the results suggest that patients whose 
pain was not reduced to a “mild” level of severity were still experiencing clinically 
important changes in function and health status even when those changes were not 
considered statistically significant. As one might expect, patients with higher levels of 
pain severity reported a much greater decrease in overall health status, sleep, daily 
functioning and an increase in depression.38 
A great deal of evidence supports NRS pain scales as being both valid and reliable 
when attempting to measure pain intensity across a number of different patient 
populations suffering from a multitude of pain disorders which include back pain, carpal 
tunnel syndrome, osteoarthritis and PLP.27,40 Furthermore, the NRS pain scale is the 
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primary basis for the World Health Organization’s (WHO) analgesic ladder with an 
emphasis on differentiating pain severity into “mild”, “moderate” and “severe” 
categories.27  
 
Secondary Outcome Measures 
SF-36 Health Survey 
 Secondary outcomes of the proposed study will be changes in quality of life as 
assessed by the SF-36 Health Survey. The SF-36 is a self-administered questionnaire that 
contains 36 items, takes approximately five minutes to complete and has been used as an 
outcome measurement instrument to assess quality of life in amputees.41,42 The SF-36 
evaluates eight aspects of general health to include: 1.) Physical functioning, 2.) Body 
pain, 3.) Role limitations due to physical health problems, 4.) Role limitations due to 
personal or emotional problems, 5.) General mental health, 6.) Social functioning, 7.) 
Energy, and 8.) General health perceptions.16 The maximum score in each section is 100 
with higher scores demonstrating a higher quality of life.42 An increase or decrease of 5 
units has been shown to be clinically relevant.16 Numerous studies investigating potential 
treatments for symptoms related to painful neuropathy have included quality of life 
measurements as a secondary outcome.11,20-22,35,43,44  
In a 1992 study, Brazier et al. sought to test the acceptability, validity and 
reliability of the SF-36 health survey questionnaire form using 1,980 patients who varied 
in age from 16-74 years old. Brazier et al. wanted to identify a questionnaire that was 
brief, easy to use and preferably self-administered. Overall, the data showed a response 
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rate of 83% and the rate of completion for each dimension was greater than 95%. 
Additionally, the SF-36 was able to detect very low levels of ill health in patients who 
had previously been deemed to be in good health per the screening of alternative quality 
of life assessment forms. The researchers concluded the SF-36 Health Survey Form was 
easy to use, acceptable to the patients and fulfilled very strict criteria of both test-retest 
reliability as well as validity and proclaimed the SF-36 to be a promising instrument for 
measuring overall health perception.41 Overall, the SF-36 is a reliable tool for assessing 
quality of life metrics in an amputation population with a specificity of 92% and a 
sensitivity of 71%.41,45 
 
Change In NRS Pain Scale Cut-Off Levels 
While a reduction in pain of two points on a 10 point scale from baseline on the 
NRS Pain Scale has been shown to be statistically significant, changes in NRS Pain Scale 
cut-off levels are important indicators to measure the extent to which a particular 
treatment if effective at reducing pain either from “severe to moderate” or “moderate to 
mild”.27,37,38 Furthermore, changes in pain scale cut-off levels serves as a measure of a 
clinically important difference.38 These changes in pain scale cut-off levels may in fact 
demonstrate the patient-care implications of clinical research study results.27,37 
 
Sample Size 
With many of the trials for the treatment of PLP using small study sizes, a 
demonstrated need for additional studies is apparent with an emphasis on appropriate 
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effect sizes.10 Most studies have been short-term assessments of vastly underpowered 
studies, which directly inhibits the detection of significant differences between groups.5 
Estimating the sample size from appropriately powered neuropathic pain trials is crucial 
for yielding useful data (see Table 2.2 Summary of Published Clinical Trials Sample Size 
Data).11 Furthermore, attrition estimates are important for pain trials given the higher than 
average dropout rates experienced.20 Studies of a similar design as this one have 
experienced a 20-25% attrition rate.11,15  











1.26 90% 2.12 0.05 
LESSER, 2004 1.3 90% 2.5 0.05 
FREYNHAGEN, 
2005 
1.26 95% 2.12 0.05 
SABATOWSKI, 
2004 
1.3 90% 2.5 0.05 
DWORKIN, 
2003 
1.3 90% 2.35 0.05 
 
 
2.4    Conclusion 
 Several studies have shown pregabalin to be effective in the treatment of painful 
neuropathic symptoms such as DPN and PHN.9,11,12,18,19,21 To date, there have been no 
studies performed investigating the effect of pregabalin in the treatment of symptoms 
related to PLP. Randomized controlled trials with adequate sample sizes are needed to 
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Chapter Three: Study Methods 
3.1    Study Design 
This study aims to conduct a multi-centered, double blinded, placebo-controlled, 
15-week randomized controlled trial to evaluate the effect of pregabalin in patients who 
experience PLP, defined as a painful sensation in an amputated limb.  
 
3.2    Study Population and Sampling 
For my methods, we intend to use a stratified sampling of United States Veterans 
of military service who have had a previous amputation and are currently experiencing 
symptoms related to PLP. The recruitment period will last a total of 16 months.  
Inclusion criteria will consist of greater than six months time between time of amputation 
and start of the study, confirmation of neuropathic pain via a score of 12 or greater on the 
LANSS, and average daily pain of 4/10 or greater. Female subjects must be non-pregnant 
and non-lactating. Exclusion criteria will consist of: subjects with any other form of 
painful neuropathy (B12 deficiency, hypothyroidism, uremia, diabetic peripheral 
neuropathy, etc.) or subjects with a creatinine clearance rate ≤ 60 mL/min using the 
Cockcroft-Gault equation. Inclusion criteria will be reviewed by a board-certified 
neurologist prior to randomization. Baseline laboratory tests obtained prior to the start of 
the study will include a hematological panel (hemoglobin, hematocrit, complete blood 
cell count (CBC), chemistry panel (AST, ALT, BUN, Creatinine, glucose, potassium) 
and a urinalysis. 
Baseline characteristics will be analyzed to account for any potential confounders 
not omitted via the inclusion and exclusion criteria. These characteristics include: age, 
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gender, race, initial level of pain, duration and location of symptoms, BMI, blood 
pressure and laboratory results (see Table 3.1 Clinical Characteristics).  
Table 3.1. Clinical Characteristics 
3.3    Participant Protection and 
Confidentiality 
Prior to the start date, the Yale University 
Human Investigation Committee will 
approve all parameters of the study. 
Additionally, there will be a strict 
adherence to all documentation required by 
the Yale Human Research Protection 
Program including an Informed Consent 
Form, which explicitly lists the details of 
the study as well as describes any inherent 
risks associated with the use of pregabalin 
treatment in an easily understood language 
format [Appendix B]. A copy of the 
Informed Consent Form will be made 
available to all participants at the time of 
signing. 
 All members of the investigation team will be required to have up-to-date Health 
Insurance Portability and Accountability Act (HIPAA) training as well as provide proof 
of training prior to the start of the study. All participants will sign a Privacy Rule 
Age (years)  
     18-50 
     51-60 
     61-70 
     >70 
Gender 
     Male 
     Female 
Race 
     Non-Hispanic White 
     Non-Hispanic Black 
     Mexican American 
     Other race/ethnic groups 
Initial Level Of Pain 
     4-6 (Moderate) 
     7-10 (Severe) 
Duration of Symptoms (years) 
     ≥1 year 
     1-2 years 
     3-5 years 
     5+ years 
     10+ years 
Anatomic Location of Amputation 
     Upper Limb 
     Lower Limb 
Body Mass Index (kg/𝒎𝟐) 
     <18.5 
     18.5-24.9 
     25-29.9 
     ≥30 
Blood Pressure (mm Hg) 
     <140/90 
     ≥140/90 
Lab Results at Baseline 
     CBC 
     LFT 
     Hemoglobin A1c 
     Urinalysis 
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Authorization Form that outlines the participants understanding of their consent to share 
health information as well as medical record information with the investigation team 
[Appendix C]. Printed copies of the Privacy Rule Authorization Form as well as a copy 
of the Patient’s Bill of Rights will be provided to the participant prior to the start of the 
study in keeping with the Health Insurance Portability and Accountability Act of 1996. 
 Any and all information obtained throughout the course of the study will be 
password protected on a computer specifically designated for the study. Access will only 
be granted to members of the research team who are required to utilize the information 
for study purposes. Individual user ID’s and passwords will be required for each member 
of the investigation team who requires access to the patient information in accordance 
with Yale University Information Technology Services policies and procedures. 
Participants of the study will receive a unique patient identifier at the start of the study to 
maintain the double-blind status of the study as well as protect the participants’ identity. 
All identifying information will be destroyed upon completion of the study. 
 There are no serious risks anticipated with participating in this study. All 
participants will be made aware of all known side effects of pregabalin prior to the start 
date of the study. Participants will be required to meet face-to-face with an affiliated 
board-certified neurologist throughout the course of the study. The neurologist will 
evaluate any and all concerning symptoms or side effects that may be experienced from 
the pregabalin treatment (see Table 3.2 Summary of Clinical Visits). Additionally, 
participants may reach a member of the investigation team at any time if they develop 
any symptoms or side effects throughout the duration of the study.  
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Table 3.2. Summary of Clinical Visits 
 BASELINE WEEK 5 WEEK 10 WEEK 14 
Full Neurological 
Exam 
X X X X 
Pain Diary X X X X 
LANSS X    
SF-36 X   X 
Labs X   X 
Creatinine 
Clearance 
X    
Assess for 
Adverse Effects 
 X X X 
 
3.4    Recruitment 
 Participants for this study will be recruited from various Department of Veteran 
Affairs hospitals throughout the United States. Recruitment will be achieved through a 
coordinated effort through the Department of Veterans Affairs with the study relying 
heavily on clinician referrals of likely study candidates, as well as strategic placement of 
recruitment flyers throughout Veteran Affairs hospitals [Appendix A]. 
 All potential study participants will be informed that the goal of this 15-week 
study is to evaluate the effect of pregabalin in symptoms related to PLP in post-
amputation patients. Participants will be made aware their involvement in this study 
could provide the necessary evidence to better assist clinicians in the treatment of PLP as 
no gold-standard treatment currently exists. Likewise, they will be made familiar with the 
study design detailed in the Informed Consent Form, which includes the baseline history 
and physical, required lab work prior to the start of the study to prevent confounding as 
well as to ensure patient safety, as well as the necessity of providing a weekly pain score 
to the investigation team [Appendix B]. Informed Consent Forms will explicitly state that 
all participants may withdraw from the study at any time. Lastly, participants in the study 
will be informed they will receive all medications, forms associated with the study, 
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laboratory testing and ongoing medical examinations free of charge for the duration of 
the study, however no additional compensation will be provided to the participant at any 
time.  
 
3.5    Randomization and Assignment of Intervention   
 Following the initial week-long baseline phase, all participants will be 
randomized via a simple randomization technique using computer generated random 
numbers into either the pregabalin interventional arm or the placebo control arm for the 
15 week duration of the study. All members of the research team as well as the study 
participants will be blinded to the group assignments until the conclusion of the study. 
Active drug and placebo will be randomized and marked via identification numbers to 
maintain the integrity of the double-blinded status of the study. 
 
3.6    Adherence and Adverse Effects  
 Participants in each arm of the study will provide weekly updates of their pain 
status via an automated IVR System. Additionally, study participants will be required to 
complete a week-long compliance assessment during which they will report their pain 
levels for one week awhile taking a placebo. Compliance will be monitored via RFID 
technology and study subjects will be asked to return their medication packaging at the 
end of the compliance assessment and routinely throughout the study to monitor ongoing 
compliance. The participants will also fill out a health survey form during the baseline 
week and again at the completion of the study in order to monitor any changes in quality 
of life factors.  
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 Study participants will have face-to-face visits with a board-certified neurologist 
periodically throughout the study. Those visits will be scheduled during the baseline 
compliance week, week 5 and week 10, with a final visit to occur during the last week of 
the study. Neurologists will be blinded to whether the participant has been randomized to 
the pregabalin arm or the placebo arm of the study. Serious adverse effects are not 
anticipated as the Food and Drug Administration has approved pregabalin for the 
treatment of similar symptoms diabetic neuropathies. However, in the event that a 
participant experiences an adverse reaction, the participant will be instructed to notify the 
investigation team. A neurologist will review the symptoms with the study participant 
and decide whether they should continue with the study. If the experienced side effects 
are intolerable or deemed dangerous by the neurology team, the study participant will be 
removed from the study. The participant will fill out end-of-study questionnaires at the 
time of removal from the study.  
 
3.7    Study Variables, Measures and Data Collection 
 The independent variable will be an oral dose of pregabalin of 300 mg/day (100 
mg every 8 hours) with an initial week-long titration phase and a week-long taper phase 
during the final week of the study (see Figure 3.1 Pregabalin Dosage Titration Schedule 





Figure 3.1. Pregabalin Dosage Titration Schedule 
 
 
The control will be the placebo medication receiving placebo medication that 
identical to the active drug. The primary dependent variable is the mean change in pain 
from baseline in the treatment arm as compared to the placebo arm. The secondary 
dependent variable is improvement in quality of life measurements in the treatment arm 
as compared to the placebo arm. Both arms of the study will be permitted to use 
acetaminophen and NSAID’s as needed for breakthrough pain. Use of rescue pain 
medication will be logged via the IVR System and analyzed post hoc.  
Pain will be logged daily beginning with the baseline compliance week and 
continuing until the completion of the study at the end of week 15. Study participants will 
be asked to record their pain on a pain scale [Appendix D] and log their pain into a pain 


















MONDAY 50 mg 100 mg 100 mg 
TUESDAY 50 mg 75 mg 75 mg 
50 mg WEDNESDAY 50 mg 50 mg 
THURSDAY 25 mg 25 mg 50 mg 
25 mg FRIDAY 25 mg 25 mg 
SATURDAY 25 mg - 25 mg 




(IVR) System. Mean weekly pain scores will be calculated and compared in order to 
assess what effect pregabalin has on overall pain. Labs to be collected during the baseline 
visit as well as the final visit will include a CBC, LFT, Hemoglobin A1c and a urine 
sample for a routine urinalysis. Data and information obtained during all face-to-face 
visits as well as lab results will not be made available to the investigation team until after 
the completion of the study. To measure participant compliance in respect to taking the 
study medication, RFID technology will be incorporated, and the data will be graphically 
plotted for analysis. To measure the primary outcome, a NRS tool for self-reporting of 
Pain will be logged at baseline as well as daily during the duration of the study 
[Appendix D]. To measure the secondary outcomes, a SF-36 Health Survey will be 
completed at baseline as well as at the completion of the study [Appendix F]. 
 
3.8    Sample Size 
To successfully complete this study, it is estimated a total of 142 participants will 
be required (71 participants assigned to each arm of the study) in order to detect a mean 
change in patient-reported pain of 1.3 from baseline using the NRS Pain Scale. This 
statistically significant difference was established using similar pain studies as well as 
literature validating the accuracy of the NRS Pain Scale. In order to estimate the sample 
size, a T test calculator (Power and Precision version 4. 2000 Biostat, Inc. Engelwood, 
NJ.) was used to compare two independent means for a two-sided alpha of 0.05 and a 
power of 80%. Additionally, the sample size of 142 participants also takes into account 




3.9    Analysis 
All data collected throughout the duration of this study will be analyzed using 
Statistical Analysis software. In order to reduce confounders, baseline characteristics for 
descriptive statistics will be stratified according to: age, gender, race, duration of 
symptoms, initial level of pain, anatomic location of the amputation, body mass index 
and blood pressure. In order to assess the primary and secondary outcomes, the 
participants will fill out various forms including: the LANSS Pain Scale [Appendix E], 
SF-36 Health Survey [Appendix F], NRS Tool for Self Reporting Pain [Appendix D] and 
Pain Diary [Appendix G]. All analysis will be carried out utilizing the Intent-to-Treat 
population, defined as any patient who received at least one dose of study medication. 
Primary analysis of the data will be conducted using ANCOVA with treatment and 
cluster, or group of centers, as fixed effects and baseline scores as the covariate adjusting 
for the use of concomitant medications, which include NSAIDs and acetaminophen. 
Secondary analysis of the data will be conducted using Linear Regression adjusting for 
baseline pain. Adverse effects will be analyzed using Fisher’s exact test. 
 
3.10    Timeline and Resources 
 A total of 21 months will be required for the completion of this study. 16 months 
will be dedicated solely to participant recruitment. Following the recruitment phase, there 
will be a one week baseline and compliance phase, one week for the dose escalation 
phase, 12 weeks for the dose stability phase, and one week of the dose taper phase for a 
total intervention time of 15 weeks. The remaining five weeks will be dedicated to 
compiling data as well as statistical analysis.  
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 Study headquarters will be housed at the Department of Neurology at the West 
Haven Veteran Affairs Hospital located at 950 Campbell Ave, West Haven, CT. Study 
personnel will include the student primary investigator, Brandon Beattie, PA-SII as well 
as the thesis advisor and primary investigator, Huned Patwa, MD. A team of board-
certified neurologists will be required in order to conduct baseline history and physicals 
as well monitor participants throughout the course of the study for any potential adverse 
effects to the medication. A phlebotomist will be required for initial baseline laboratory 
draws as well as end-of-study laboratory draws. A dedicated research assistant will be 
necessary in order to assist the investigation team with patient consents as well as data 
consolidation and analysis. A statistician will be needed at the conclusion of the 
interventional time to assist with statistical analysis of the data.  
 Required resources include the pregabalin medication as well as placebo 
medication in the form of a sugar pill identical to the shape and color of the pregabalin as 
well as over-the-counter strength acetaminophen and NSAIDs for concomitant analgesic 
use in both the control arm and placebo arm of the study. This is an imperative detail 
necessary to maintain the double-blinded status of the study in order to minimize bias. 
Pregabalin dosages of both 25 milligram (mg) and 50 milligram (mg) pills are necessary 
in order to successfully complete the titration phase and dose-taper phase of the 
intervention period.  Equipment needed for the study includes a dedicated phone line, a 
workspace with computer access, a RFID enabled smartphones and RFID labels as well 
as an automated IVR System through which study participants to record their weekly 
pain scale results and total number of medication doses taken during the day. 
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Chapter Four: Conclusion 
4.1    Advantages and Strengths   
Overall, this study has several strengths. Strict inclusion and exclusion criteria 
will be utilized as well as an analysis of baseline characteristics in an effort to minimize 
possible confounders. Additionally, the study will be utilizing pain scales and quality of 
life metrics that have been well validated in previous studies.1-5 Another strength of the 
study is the chosen timeline. Ko et al. have shown the appropriate study duration for 
investigating chronic pain should be 12 weeks or greater in order to verify durability of 
the desired response.4 Lesser et al. were able to show a statistically significant difference 
in pain with the treatment of pregabalin but the study only lasted five weeks. This study 
is scheduled to last a total of 15 weeks (one week for the dose escalation phase, 12 weeks 
for the dose stability phase and a final week for the dose taper phase). Strength of this 
proposed study also comes in the form of the choice to pool subjects from U.S. 
Department of Veteran Affairs hospitals. VA hospitals utilize a comprehensive 
standardized electronic medical record system allowing for relatively easy access to a 
large patient population thereby minimizing potential research obstacles. 
 
4.2    Disadvantages and Limitations 
While great strides were made to formulate a comprehensive study design, this 
study is not without potential limitations. As no biomarker or gold standard for 
diagnosing PLP exists, there is a possibility of including subjects into the study who are 
experiencing pain from sources other than PLP. This study only utilizes one dosage of 
pregabalin in the control arm rather than investigating the possible effect multiple 
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dosages may have on the treatment of symptoms related to PLP. Future studies may wish 
to further stratify the control arm into cohorts who are given multiple dosages of 
pregabalin. Additionally, this study utilized a single treatment modality rather than a 
multiple treatment modality. Future studies may wish to focus on what effect, if any, a 
combination regimen of pregabalin alongside medications such as tramadol or 
acetaminophen may have in respect to a better potential therapeutic response versus the 
use of a single agent alone.4,6,7  
Furthermore, the source of patient sampling may pose a possible issue in terms of 
the generalizability of the study results. While recruiting patients from the Department of 
Veteran Affairs certainly has advantages, one potential setback is the potential risk of 
decreasing the generalizability of the results given the unique characteristics of a veteran 
population. Lastly, while this study did incorporate tools for assessing overall quality of 
life through the use of the SF-36 Health Survey Form, there was no emphasis on what 
effect, if any, sleep disturbances may have on overall quality and severity of PLP. Sleep 
disturbances have been shown to have a direct effect on pain. 8 Future studies may wish 
to incorporate a baseline polysomnography (PSG) sleep study and compare these results 
to end-of-study PSG results to further elicit what effect sleep disturbances have on PLP.8  
 
4.3    Clinical Implications 
PLP is a devastating pain syndrome affecting up to 80% of all post-amputation 
patients with no clear gold standard of treatment.7,9 By 2050, an estimated 3.6 million 
Americans will have an amputation as a result of either trauma, medical complications or 
disease progression.7 Given this estimate, a need clearly exists for well designed trials 
investigating potential treatment options for PLP. Pregabalin is proven to be effective for 
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the treatment of painful neuropathic symptoms in syndromes such as DPN and PHN and 
may have the potential to be a useful treatment option for PLP.5,10,11 If proven effective, 
implications of pregabalin as a treatment regimen for PLP could significantly reduce 
painful symptoms, be a cost effective option and vastly improve the quality of life of 
individuals suffering from PLP.12 Results of this study may also provide substantial 
evidence to better assist the U.S. Department of Veterans Affairs in standardizing the 
treatment of PLP in veterans experiencing PLP who have either lost a limb as a direct 
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Appendix B: Informed Consent Form 
 
 





This Informed Consent Form is for men and women who have had an upper or lower limb 
amputation via either traumatic or surgical removal and experience symptoms related to 
Phantom Limb Pain who are invited to participate in a research study. This study aims to 
research what effects pregabalin may have in decreasing pain and discomfort associated 
with Phantom Limb Pain. 
 
Name of Principal Investigator: Brandon Beattie, PA-SII and Huned Patwa, MD 
Name of Organization: Yale University Physician Associate Program 
Name of Proposal: The Effect of Pregabalin in Patients With Phantom Limb Pain: A 
Randomized Controlled Trial 
 
This Informed Consent Form has two parts: 
• Information Sheet (to share information about the research with you) 
• Certificate of Consent (for signatures if you agree to take part) 
 
You will be given a copy of the Informed Consent Form in its entirety 
 
PART I: Information Sheet 
 
Introduction 
I am Brandon Beattie, a Yale University Physician Associate student. I aim to research 
possible treatment options for Phantom Limb Pain, a devastating syndrome effecting up to 
80% of individuals who have had an arm or leg amputation. Here you may find information 
related to the study in order to better assist you with deciding if you would like to 
participate in the research. You do not have to decide today whether or not you would like 
to participate. 
 
If you do not understand any words or descriptions related to the study, please ask for 
clarification and someone from the research team will take the time to explain them as 
clearly as possible to you. If you have any questions or concerns at a later date and time, 
you may direct them to any of the research team members. 
 
Purpose of the research 
Phantom Limb Pain is defined as pain in a region of the body that has been removed due 
to amputation and is very commonly experienced after an amputation of an upper or lower 
limb. The treatment options currently used to help people suffering from Phantom Limb 




and decreased quality of life. There is a medication, pregabalin, that has been studied 
extensively in the diabetic population for the treatment of neuropathic pain (pain 
originating from the nerves). We believe pregabalin may help with the treatment of pain 
related to Phantom Limb Pain in amputation patients as well, however the use of pregabalin 
for the treatment of symptoms related to Phantom Limb Pain has not been previously 
studied. The reason we are doing this research is to determine if pregabalin is effective in 
the treatment of pain and discomfort associated with Phantom Limb Pain. 
 
Type of Research Intervention 
This research will involve taking a pill three times a day as well as asking you to document 
your pain using a form that will be provided to you. The pill may be the medication 
pregabalin or it may be a placebo in which case no active drug will be administered. You 
will be randomly assigned to either the medication group or the placebo group and neither 
you nor the research team will be made aware of whether you have been assigned to the 
medication group or placebo group until after the 15-week trial has finished.  
 
Participant selection 
We are inviting all adults who have had an amputation of an upper or lower limb and who 
meet all of the inclusion criteria parameters to participate in research to determine if the 
drug, pregabalin, is effective in the treatment of pain and quality of life in individuals 
suffering from symptoms related to Phantom Limb Pain. 
 
Voluntary Participation 
Your participation in this research study is completely voluntary. All healthcare services 
you receive from your clinicians will continue during the duration of the study. If you 
choose not to participate in this research study, you will continue to be offered treatment 
options routinely used in the treatment of your symptoms. You may opt to remove yourself 
from the study at any time. 
 
Information on the Trial Drug  
The drug we are testing in this research is called pregabalin. It has been tested extensively 
before in people who do not have symptoms related to Phantom Limb Pain but who 
experience nerve pain related to worsening diabetic complications. We now want to test 
the medication on people who have pain and decreased quality of life due to Phantom Limb 
Pain. This is called a “phase 2” trial. 
 
You should know that pregabalin has a few known side effects. Side effects of pregabalin 
include unusual tiredness or weakness, dizziness, angioedema or peripheral edema 
(swelling of the face, mouth, or extremities), hypersensitivity, suicidal behavior, and 
weight gain. Less common side effects include labored breathing and shortness of breath. 
As your body adjusts to the medication, these side effects may go away in the event you 
do experience them. We know of no other problems or risks associated with the use of 
pregabalin. 
 
Some participants of this research study will not be given the drug pregabalin. Instead, they 
will be given a placebo pill that contains no active medication. This is to better understand 
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the effects pregabalin may have on treating the symptoms related to Phantom Limb Pain. 
If you decide to participate in this research study, you will be randomly assigned to either 
the pregabalin group or the placebo group. During the duration of the 15-week study, 
neither you nor members of the research team will know which group you have been 
assigned to. There is no known risk associated with the placebo pill. 
 
Procedures and Protocol 
A. Unfamiliar Procedures 
For this study, we need to compare two groups of people who experience Phantom Limb 
Pain: one group who will receive the medication pregabalin and another group who will 
receive a placebo. A placebo is an inactive medication that looks identical to the real 
medication. This is so the research team nor the participant are aware if they are taking the 
actual medication or the placebo in order to best decide how well a medication works for 
a particular illness or symptom relief. Over-the-counter strength acetaminophen and 
NSAIDs will be permitted throughout the duration of the study.  
 
The groups will be selected at random. It is important that neither you, as the participant, 
nor your research team know which group you have been placed in so that the results will 
not be influenced unintentionally. The two groups will then be compared at the end of the 
trial. Healthcare workers will be monitoring you and the other participants very carefully 
throughout the course of this study. If you have any concerns or worries during the course 
of the study, please bring these up either to myself or any member of the research team. 
 
B. Description of the Process 
During the first visit, you will be asked to answer a series of easy to understand 
questionnaires in order to establish what your baseline pain and quality of life is. Following 
the initial visit, we will then ask you to track your daily pain for a total of 7 days while 
taking a sugar pill as well as calling a toll-free number to record your daily pain scale. This 
is to verify your willingness to comply with the research study process. 
 
During the next week, we will begin a week-long period of dose escalation. You will be 
asked to take one (1) 50 mg tablet three (3) times a day for one week. You will also be 
asked to log your pain in a daily log that will be provided to you as well as record your 
weekly pain scale via telephone.  
 
Following the dose escalation period, you will be asked to take one (1) 100 mg tablet three 
(3) times a day for 12 weeks. During this period, you will be asked to continue to log your 
pain in a daily log that will be provided to you as well as record your weekly pain scale via 
the telephone. Compliance in respect to taking the medication as directed will be monitored 
via radiofrequency identification (RFID) technology within the medication packaging. 
 
The last week of the study will consist of a 1-week tapering period where you will gradually 
be reducing your dose as directed in order to minimize any adverse effects of discontinuing 





This research study is scheduled to last a total of 15 weeks. During that time, it will be 
necessary for you to meet with the research team periodically. We will do our best to 
conduct most of our interviews over the phone, face-to-face meetings are important during 
the initial week and necessary occasionally throughout the course of the study in order to 
insure your safety as well as the integrity of the study.  
 
Side Effects 
As previously mentioned, the medication pregabalin may have some unwanted side effects. 
This may include unusual tiredness or weakness, dizziness, angioedema or peripheral 
edema (swelling of the face, mouth, or extremities), hypersensitivity, suicidal behavior, 
and weight gain. Less common side effects include labored breathing and shortness of 
breath. The research team will monitor you closely throughout the course of the trial and 
keep track of any unwanted side effects or problems. 
 
Risks 
Pregabalin has been approved by the U.S. Food and Drug Administration for use in 
patients experiencing diabetic neuropathy and researched extensively in the diabetic 
community. With that said, there is always the potential for harm when introducing a new 
medication to your body. We will do everything we can to decrease the likelihood of any 
adverse events.  
 
Benefits  
With your participation in this research study, you will be provided all medications free of 
charge. Additionally, you will be compensated for any travel expenses you incur during 
the few times the research team must meet with you in person throughout the course of the 
study. You may not experience any personal benefits from participating in this study, 
however your participation is crucial in order to help investigate if pregabalin is helpful in 
the treatment of pain and a decreased quality of life due to symptoms related to Phantom 
Limb Pain.  
 
Confidentiality 
Throughout the course of this study and afterward, your confidentiality is of the utmost 
importance to your research team. Any information collected from you will be marked with 
an identification number rather than your name or personal information. Only the research 
team will know the names of the participants in this study. Names or personal information 
will never be published or released.  
 
Right to Refuse or Withdraw 
You do not have to participate in this research study if you do not wish to do so. You may 
also remove yourself from the study at any point during the 15-week period if you wish to 
do so. Please contact a member of the research team if at any point you decide you no 
longer wish to participate in the research study. 
Point of Contact 
If you have any questions or concerns, you may contact me at any time. I may be reached 
via email at brandon.beattie@yale.edu or you may write to me at: 
 54 
 
Brandon Beattie, PA-SII 
Yale School of Medicine 
333 Cedar Street 
New Haven, CT 06510 
 
This proposal has been reviewed and approved by the Yale University Physician 
Associate Program Thesis Committee, Yale University Institutional Review Board 
(IRB) and Human Investigation Committee (HIC) whose tasks are to make sure that 
research participants are protected from harm or unnecessary risk.  
 
 
PART II: Certificate of Consent 
 
I have read the foregoing information, or it has been read to me. I have had the opportunity 
to ask questions about it and any questions that I have asked have been answered to my 
satisfaction.  I consent voluntarily to participate as a participant in this research study. 
 






____________________________    ______________ 
Signature of Principal Investigator    Date 
 
  or 
 
_______________________________   ______________ 
Signature of Person Obtaining Consent    Date 
 
 











VALID ONLY THROUGH: 
__________________ 
 
HR PROTOCOL #: INITIALED: 
________________     ________________ 
 55 
Appendix C: Privacy Rule Authorization Form 
YALE UNIVERSITY 
Authorization To Use Personal 
Health Information In Research 
 
 
Study Title: The Effect of Pregabalin in Patients With Phantom Limb Pain: A Randomized Controlled 
Trial 
 
Principal Investigator(s): Brandon Beattie, PA-SII and Huned Patwa, MD 
 
 
Participant Name: ___________________________________________________ 
 
Medical Record Number: _____________________________________________ 
 
Before researchers use or share any health information about you as part of this study, Yale 
University is required to obtain your authorization. This helps explain to you how this 
information will be used or shared with others involved in the study.   
 
• Yale University and its hospitals, clinics, health-care providers and researchers are 
required to protect the privacy of your health information.   
• You should have received a Notice of Privacy Practices when you received health care 
services here.  If not, let us know and a copy will be given to you.  Please carefully 
review this information. Ask if you have any questions or do not understand any parts of 
this notice. 
• If you agree to take part in this study your health information will be used and shared 
with others involved in this study. Also, any new health information about you that 
comes from tests or other parts of this study will be shared with those involved in this 
study. 
• Health information about you that will be used or shared with others involved in this 
study may include your research record and any health care records at Yale University. 
For example, this may include your medical records, x-ray or laboratory results.  
Psychotherapy notes in your health records (if any) will not, however, be shared or used. 
Use of these notes requires a separate, signed authorization. 
 
Please read the information carefully before signing this form. Please ask if you have any 
questions about this authorization, the University’s Notice of Privacy Practices or the study 
before signing this form. 




Those Who May Use, Share and Receive Your Information As Part Of This Study 
• Researchers and staff at Yale University will use, share and receive your personal health 
information for this research study. Authorized Yale staff not involved in the study may 
be aware that you are participating in a research study and have access to your 
information. If this study is related to your medical care, your study-related information 
may be placed in your permanent hospital, clinic or physician’s office records.   
 
• Those who oversee the study will have access to your information, including: 
o Members and staff of Yale University’s Institutional Review Board (IRB) and 
Human Investigation Committee (HIC) 
o University data safety monitoring committees  
o Yale University Office of Research 
 
• Your health information may also be shared with federal and state agencies that have 
oversight of the study or to whom access is required under the law. These may include: 
o The Food and Drug Administration 




• This authorization will not expire unless you change your mind and revoke it in writing. 
There is no set date at which your information will be destroyed or no longer used.  This 
is because the information used and created during the study may be analyzed for many 
years, and it is not possible to know when this will be complete.   
 
Signing the Authorization 
 
• You have the right to refuse to sign this authorization.  Your health care outside of the 
study, payment for your health care, and your health care benefits will not be affected if 
you choose not to sign this form.  
• You will not be able to take part in this study and will not receive any study treatments if 
you do not sign this form. 
• If you sign this authorization, you may change your mind at any time. Researchers may 
continue to use information collected up until the time that you formally changed your 
mind.  If you change your mind, your authorization must be revoked in writing.  To 
revoke your authorization, please write to: 
Brandon Beattie, PA-SII 
Yale School of Medicine 
333 Cedar Street 






• Signing this authorization also means that you will not be able to see or copy your study-
related information until the study is completed. This includes any portion of your 
medical records that describes study treatment.  
 
Contacts for Questions 
 
• If you have any questions relating to your privacy rights, please contact Brandon Beattie, 




I have read (or someone has read to me) this form and have been able to ask questions. All of my 
questions about this form have been answered to my satisfaction.  By signing below, I permit 
Brandon Beattie, PA-SII and Huned Patwa, MD and the others listed on this form to use and 




(Participant or Legally Authorized Representative) 
 
Name _____________________________________________________________  
(Print name above) 
(If legal representative, also print relationship to participant.) 
 























































Source: Farrar JT, Young JP, Jr., LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity 
measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149-158. 
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Have you felt downhearted and blue?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit  of the time
None of the Time
Did you feel worn out?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit  of the time
None of the Time
Have you been a happy person?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit  of the time
None of the Time
Did you feel tired?
All of the time
Most of the time
A good Bit of the Time
Some of the time
A little bit  of the time
None of the Time
SOCIAL ACTIVITIES:
During the past 4 weeks,  how much of the time has your physical health or emotional  problems interfered with
your social activities (like visiting with friends, relatives, etc.)?
All of the time
Most of the time
Some of the time
A little bit  of the time








Source: Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life 









Appendix H: Sample Size Calculation 
 In order to estimate the sample size, a T test calculator (Power and Precision 
version 4. 2000 Biostat, Inc. Engelwood, NJ.) was used to compare two independent 
means for a two-sided alpha of 0.05 and a power of 80%. To detect a mean change in 
patient-reported pain of 1.3 from baseline using the NRS Pain Scale using a standard 
deviation of 2.5, 71 participants will be required in each arm of the study for a total 
sample size of 142 participants. The effect size was assumed using similar studies that 
have demonstrated a mean change in patient-reported pain of 1.3 from baseline as being 
statistically significant. The dropout rate for this study was estimated to be 20% to take 
into account the higher than usual attrition rates demonstrated in previous pain studies 








Standard Deviation 2.5 
 
Mean Change In Patient-Reported Pain 




Estimated Attrition Rate 20% 
 
Calculated Sample Size (Per Arm) 71 participants in each arm of the study  
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